Loading...
Guest User
Welcome! Please login.
| IPO Listing At | BSE, NSE |
| IPO Issue Type | Book Build Issue |
| Issue Size | ₹152.46 Cr |
| Fresh Issue | ₹152.46 Cr |
| Face Value | ₹10 Per Equity Share |
| Price Band | ₹133.00-140.00 per share |
| Discount | Retail: 0.00 |
| BSE Code | 543998 |
| NSE Code | VALIANTLAB |
| Registrar | MUFG Intime India Pvt.Ltd. |
| Lead Managers | Unistone Capital Pvt.Ltd. |
| Allotment Status | |
| DRHP | |
| RHP | |
| Final Prospectus | |
| Anchor List |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 105 shares and in multiples thereof
Incorporated in 1980, Valiant Laboratories Limited is a pharmaceutical ingredient manufacturing company in India having focuses on manufacturing Paracetamol.
The company's manufacturing unit is located in Palghar, Maharashtra, spread across 2,000 sq. mts. of land with an aggregate annual total installed capacity of 9,000 MT per annum. Valiant Laboratories also has an R&D Facility, equipped with an analytical laboratory and infrastructure for developmental activities in existing products.
For the Fiscal 2023, Fiscal 2022 and Fiscal 2021, Valiant Laboratories revenue from operations was Rs. 3,339.10 million, Rs. 2,915.23 million and Rs. 1,823.69 million, respectively.
Valiant Laboratories Limited imports Para Amino Phenol, being the raw material for the manufacture of Paracetamol from China and Cambodia.
As of April 30, 2023, Valiant Laboratories has 86 employees.
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Investment in VASPL for partfinancing its capital expenditure requirements in relation to the setting up of the Proposed Facility | 80.00 |
| 2 | Investment in VASPL for funding its working capital requirements; and | 45.00 |
| 3 | General corporate purposes | 9.32 |
| Total | 134.32 |
| Period Ended | 31 Mar 2023 | 31 Mar 2022 | 31 Mar 2021 |
|---|---|---|---|
| Assets | 212.76 | 181.81 | 106.31 |
| Total Income | 338.77 | 293.47 | 183.78 |
| Profit After Tax | 29.00 | 27.50 | 30.59 |
| NET Worth | 100.49 | 71.46 | 88.58 |
| Total Borrowing | 59.40 | 60.68 | 0.35 |
| Amount in ₹ Crore | |||
| KPI | |
|---|---|
| ROE | 33.73% |
| ROCE | 22.76% |
| Debt / Equity | 0.59% |
| RoNW | 28.86% |
| PAT Margin | 8.56% |
| Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 8.91 | |
| P/E (x) | 15.71 | |
| Promoter Holding | 100.00% | 74.94% |
| Market Cap | ₹608.30 Cr. | |
